Kanabo Group PLC Issue of New Ordinary Shares and TVR (5133F)
July 10 2023 - 6:19AM
UK Regulatory
TIDMKNB
RNS Number : 5133F
Kanabo Group PLC
10 July 2023
10 July 2023
Kanabo Group PLC
("Kanabo" or the "Company")
Issuance of New Ordinary Shares and Total Voting Rights
Following the Company's publication of the prospectus, announced
on 13 June 2023 ("The Prospectus"), the 38,461,492 ordinary shares
issued ("2020 Deferred Consideration Shares") in connection with
the acquisition of Kanabo Research Limited at a price of 6.5p, have
been admitted today, 10 July 2023, to the Standard List of the
London Stock Exchange ("Admission")
Following Admission, for the purposes of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, Kanabo
announces that the Company has 611,677,871 ordinary shares of 2.5p
each in issue ("Ordinary Shares"), each share carrying the right to
one vote. The figure of 611,677,871 should be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please visit
http://www.kanabogroup.com/ or contact the following:
Enquiries:
Kanabo Group plc via Vigo Consulting
Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230
Assaf Vardimon, Chief Financial Officer
Ian Mattioli, Non-Executive Chair of the
Board
Peterhouse Capital Ltd (Financial Adviser
and Broker)
Eran Zucker/ Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930
Vigo Consulting (Financial Public Relations/Investor
Relations)
Jeremy Garcia / Fiona Hetherington / Verity
Snow +44 (0)20 7390
kanabo@vigoconsulting.com 0230
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to
revolutionising patient care through its innovative technology
platform and disruptive product offerings. Since its inception in
2017, Kanabo has been focused on researching, developing, and
commercialising regulated medicinal cannabis-derived formulations
and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP
Service, provides patients with video consultations, online
prescriptions, and primary care services. The Company is a leader
in its field, focusing on improving patient outcomes and providing
more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic,
Treat It, under the expert guidance of its technological and
product expertise. Treat It initially focuses on chronic pain
management using plant-based medicine and treatments that are
currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with
the highest quality medical treatments and more accessible
healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOENKKBDKBKDPOD
(END) Dow Jones Newswires
July 10, 2023 06:19 ET (10:19 GMT)
Kanabo (LSE:KNB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Kanabo (LSE:KNB)
Historical Stock Chart
From Dec 2023 to Dec 2024
